As a Contract Research, Development, and Manufacturing Organization (CRDMO), PeptideHub offers integrated services spanning the entire peptide development lifecycle—from early discovery research through to commercial manufacturing. This integrated approach reduces technology transfer risks, accelerates timelines, and provides a single point of accountability for peptide development programs.
Our CRDMO model combines research capabilities (including assay development and lead optimization), development services (including process development and scale-up), and manufacturing (including GMP production and commercial supply). This comprehensive service offering ensures seamless progression from hit to clinic, with consistent quality and documentation throughout.
In the research phase, we provide custom peptide synthesis for target validation, SAR studies, and lead optimization. Our high-throughput synthesis capabilities enable rapid generation of libraries for screening, while our medicinal chemistry expertise guides optimization of potency, selectivity, and pharmacokinetic properties.
In the development phase, we focus on process optimization and scale-up. Our process development team works to identify the most efficient synthesis route, optimize purification conditions, and develop analytical methods for quality control. We also conduct stability studies and formulation development to support clinical progression.
In the manufacturing phase, we provide GMP production for clinical trials and commercial supply. Our GMP facility is equipped to handle batches from grams to kilograms, with full regulatory documentation and quality control. We also provide regulatory support for IND filings, including comprehensive documentation of synthesis, characterization, and stability data.
This integrated approach offers significant advantages over using multiple providers for different stages of development. By maintaining continuity throughout the development process, we minimize the risk of changes in product quality or performance during technology transfer. Our customers benefit from faster timelines, lower costs, and reduced risk, making us the partner of choice for peptide development programs.